(Q42452790)

31 October 2017

title

The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum (English)

1 reference

31 October 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

1 April 2024

author name string

D. Roseeuw

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616810

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14616810

1 April 2024

publication date

1 November 2003

1 reference

full work available at URL

31 October 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2230.28.s1.10.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2230.28.s1.10.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

Clinical and Experimental Dermatology

1 April 2024

published in

1 reference

31 October 2017

volume

28 Suppl 1

1 reference

31 October 2017

page(s)

30-32

1 reference

Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Xeroderma pigmentosum--bridging a gap between clinic and laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.10.X

The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.10.X

1 April 2024

Identifiers

1 reference

31 October 2017

1 reference